Cochrane · intervention · CD007404
Interventions for central giant cell granuloma (CGCG) of the jaws
Suárez‐Roa, MDL, Reveiz, L, Ruíz‐Godoy Rivera, LM, et al. · Cochrane Database of Systematic Reviews · 2009 · Cochrane Library
Full textEvery question was extracted from the full review (methods and results), not only its Summary of Findings table.
Questions
10
current version
GRADE rated
0
No studies
8
Included studies
1
as reported
No studies 8 · 80%Ungraded 2 · 20%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients with a pathological diagnosis of CGCG of the jaws; no restrictions on age, participants with genetic defects, size of lesion, or aggressive versus non-aggressive lesions; participants with recurrent lesions included; giant cell tumour (osteoclastoma) excluded | 14 participants with histologically confirmed CGCG in one or both jaws and normal calcium and parathyroid hormone (PTH) serum levels (one included RCT, de Lange 2006) |
| Intervention | Surgical treatment: curettage, peripheral osteotomy or resection. Non-surgical interventions: injection of corticosteroids to the lesion or subcutaneous administration of calcitonin or interferon alpha or imatinib | Calcitonin (salmon calcitonin nasal spray 200 IU/day) (n=7) |
| Comparison | Primary non-surgical versus primary surgical interventions or any other treatment or placebo | Placebo (n=7) |
| Outcomes | Primary: Recurrence. Secondary: Disease-free survival; Resectability; Overall survival; Complete remission; Partial reduction; Quality of life; Adverse events. | Increase in volume of more than 10% compared to the pretreatment measurement (n=14); Adverse events (n=14) |
| Study designs | Randomised controlled trials (RCTs) comparing primary non-surgical versus primary surgical interventions or any other treatment; quasi-randomised studies not eligible | RCT (n=1) |
| Timing | Not specified | 3 months (placebo-controlled RCT phase) |
Search date: 2009-07. Databases: Cochrane Oral Health Group's Trials Register; Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; LILACS; ClinicalTrials.gov; LATINREC; meta Register of Controlled Trials
Questions and results
Show all 2 versionsPrimary surgical intervention (curettage, peripheral osteotomy, or resection) vs Primary non-surgical intervention (intralesional corticosteroids, subcutaneous calcitonin, interferon alpha, or imatinib)
Population: Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | no estimate extracted | 0 studies | No studies |
Resectability | no estimate extracted | 0 studies | No studies |
Disease-free survival | no estimate extracted | 0 studies | No studies |
Quality of life | no estimate extracted | 0 studies | No studies |
Adverse events | no estimate extracted | 0 studies | No studies |
Complete remission | no estimate extracted | 0 studies | No studies |
Recurrence | no estimate extracted | 0 studies | No studies |
Partial reduction | no estimate extracted | 0 studies | No studies |
Calcitonin (salmon calcitonin nasal spray 200 IU/day) vs Placebo
Population: Patients with histologically confirmed CGCG in one or both jaws and normal serum calcium and parathyroid hormone (PTH) levels
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Increase in volume of more than 10% compared to the pretreatment measurement 3 months | RR 3.0 [0.40, 22.30] | 1 study · 14 participants | Ungraded |
Adverse events | Adverse events were not described separately for each group. Trialists reported that adverse events were in most patients minimal and consisted of nausea, flushes and some dizziness. One patient had diarrhoea which… | 1 study · 14 participants | Ungraded |